A Study of Gaboxadol in Primary Insomnia

A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Study of Gaboxadol in Primary Insomnia

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00209846

Enrollment

320

Registered

2005-09-21

Start date

2004-06-30

Completion date

2006-11-30

Last updated

2007-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Insomnia

Keywords

Primary insomnia

Brief summary

To evaluate the safety and tolerability of gaboxadol in primary insomnia.

Detailed description

To obtain long-term safety data in elderly patients with gaboxadol.

Interventions

DRUGGaboxadol

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

66 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients with a diagnosis of primary insomnia

Design outcomes

Primary

Measure	Time frame
Safety	—
Tolerability	—

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026